Related Experiment Video
Updated: Jun 5, 2025

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Butyrate-producing Faecalibacterium prausnitzii suppresses natural killer/T-cell lymphoma by dampening the JAK-STAT
Zhuangzhuang Shi1, Min Li2, Chen Zhang3,4,5
1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Background:
Natural killer/T-cell lymphoma (NKTCL) is a highly aggressive malignancy with a dismal prognosis, and gaps remain in understanding the determinants influencing disease outcomes.
Objective:
To characterise the gut microbiota feature and identify potential probiotics that could ameliorate the development of NKTCL.
Design:
This cross-sectional study employed shotgun metagenomic sequencing to profile the gut microbiota in two Chinese NKTCL cohorts, with validation conducted in an independent Korean cohort. Univariable and multivariable Cox proportional hazards analyses were applied to assess associations between identified marker species and patient outcomes. Tumour-suppressing effects were investigated using comprehensive in vivo and in vitro models. In addition, metabolomics, RNA sequencing, chromatin immunoprecipitation sequencing, Western blot analysis, immunohistochemistry and lentiviral-mediated gene knockdown system were used to elucidate the underlying mechanisms.
Results:
We first unveiled significant gut microbiota dysbiosis in NKTCL patients, prominently marked by a notable reduction in Faecalibacterium prausnitzii which correlated strongly with shorter survival among patients. Subsequently, we substantiated the antitumour properties of F. prausnitzii in NKTCL mouse models. Furthermore, F. prausnitzii culture supernatant demonstrated significant efficacy in inhibiting NKTCL cell growth. Metabolomics analysis revealed butyrate as a critical metabolite underlying these tumour-suppressing effects, validated in three human NKTCL cell lines and multiple tumour-bearing mouse models. Mechanistically, butyrate suppressed the activation of Janus kinase-signal transducer and activator of transcription pathway through enhancing histone acetylation, promoting the expression of suppressor of cytokine signalling 1.
Conclusion:
These findings uncover a distinctive gut microbiota profile in NKTCL and provide a novel perspective on leveraging the therapeutic potential of F. prausnitzii to ameliorate this malignancy.
Insights
Reduced Faecalibacterium prausnitzii in the gut microbiome is linked to poorer outcomes in natural killer/T-cell lymphoma (NKTCL). Restoring this bacterium may offer a novel therapeutic strategy for NKTCL patients.
Area of Science:
- Oncology
- Microbiome research
- Immunology
Background:
- Natural killer/T-cell lymphoma (NKTCL) is an aggressive cancer with poor prognosis.
- Understanding factors influencing NKTCL outcomes is crucial.
Purpose of the Study:
- To characterize gut microbiota in NKTCL patients.
- To identify potential probiotic targets for NKTCL treatment.
Main Methods:
- Shotgun metagenomic sequencing of gut microbiota in Chinese and Korean NKTCL cohorts.
- Analysis of associations between microbial species and patient survival.
- In vivo and in vitro studies to assess antitumour effects of F. prausnitzii and its metabolite, butyrate.
Main Results:
- Significant gut microbiota dysbiosis observed in NKTCL patients, with reduced Faecalibacterium prausnitzii correlating with shorter survival.
- F. prausnitzii demonstrated antitumour properties in NKTCL models, inhibiting cancer cell growth.
- Butyrate, a metabolite of F. prausnitzii, suppressed NKTCL progression by inhibiting the JAK-STAT pathway via enhanced histone acetylation and increased SOCS1 expression.
Conclusions:
- NKTCL exhibits a distinct gut microbiota profile.
- Faecalibacterium prausnitzii and its metabolite butyrate show therapeutic potential for NKTCL.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
The Intrinsic Apoptotic Pathway
The JAK-STAT Signaling Pathway

